|Bid||43.23 x 800|
|Ask||43.24 x 4000|
|Day's Range||42.85 - 43.31|
|52 Week Range||35.87 - 46.47|
|Beta (3Y Monthly)||0.43|
|PE Ratio (TTM)||22.21|
|Forward Dividend & Yield||1.44 (3.47%)|
|1y Target Est||N/A|
There has been some rather interesting activity in the markets the past month or so.
Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.
Cancer therapy stocks rallied after Pfizer made a deal to boost its oncology offerings. These industry players may also be takeover targets.
Pfizer Inc NYSE:PFEView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for PFE with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold PFE had net inflows of $8.41 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. PFE credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.
Dow Jones component Pfizer is buying biotech company Array BioPharma in an $11.4 billion deal that reaps the rewards of two approved cancer treatments. Array stock soared to a record high.
On the surface, the gains notched by the major U.S. equity benchmarks to start the week were not all that impressive. The Nasdaq Composite led the way, climbing 0.62%, while the S&P 500 and the Dow Jones Industrial Average each finished higher by 0.09%.Source: Shutterstock However, there were pockets of excitement throughout the market today, helped by the return of Merger Monday. Dow component Pfizer (NYSE:PFE), one of the largest U.S. pharmaceuticals companies, is looking to bolster its oncology offerings by acquiring cancer treatment maker Array BioPharma (NASDAQ:ARRY) for $48 a share in cash, putting an enterprise value of about $11.4 billion on the company.Pfizer has one of the larger cash stockpiles among the major U.S. pharmaceuticals companies and checks many of the quality boxes. However, there are some concerns the Array deal could be credit negative.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCredit ratings aside, traditional pharmaceuticals companies need growth, and buying makers of cancer drugs is one avenue for delivering that growth. Other ChatterApple (NASDAQ:AAPL) stock, always a widely watched bellwether as it is the largest technology name in the Dow, traded modestly higher Monday although some analysts expressed concern about the impact of the China trade war on the stock and how the company is positioned for a fuller 5G rollout next year. * 7 Top-Rated Biotech Stocks to Invest In Today "JPMorgan analyst Samik Chatterjee cut his forecast for iPhone shipments for the next few quarters by 4%, and trimmed his price target on the stock to $233 from $235," reports Barron's. "But he maintains an Overweight rating on the shares, asserting that the trade tensions are likely to be resolved."Sticking with Dow technology names for a moment, Intel (NASDAQ:INTC), one of the largest semiconductor makers, is trying to snap out of a funk that has the stock down nearly 15% in the current quarter. Much of that tumble is attributable to semiconductor companies' sensitivity to the trade war with China, but for long-term investors, there are reasons to be optimistic about Intel."We concede that 2019 will be strenuous for Intel because of macro weakness, U.S.-China tensions, and share loss, but overall revenue growth should eventually stabilize," said Morningstar in a recent note. "As Intel gets back on track in 2020 with its 10-nm Ice Lake server parts, we think its data center group, or DCG, will enjoy average top-line growth of 10% through 2023."Boeing (NYSE:BA), a frequent guest in this space and the Dow's largest component, was the blue-chip index's best performer Monday, adding 2.2%. The company said it has no plans to rename the controversial 737 max passenger jet.At the Paris Airshow Monday, the aerospace giant boosted its 20-year demand forecast for passenger jets to $6.8 trillion, up from a previous estimate of $6.3 trillion."The world's largest planemaker said at the Paris Airshow it expected 44,040 new airplane deliveries over the next two decades, up from the roughly 43,000 it forecast a year ago," according to Reuters. Bottom Line on the Dow Jones TodayOverall, a little under half of the Dow's 30 components closed higher today, hardly a great percentage and risks remain for investors to consider. Looking out to later in June, FedEx Corp. (NYSE:FDX) reports fiscal fourth-quarter results on June 25, and while the freight shipping company is not a member of the Dow Jones Industrial Average, it is a member of the Dow Jones Transportation Index, and a bellwether stock at that.Mired in a slump that has seen the shares slide almost 5% this month, FedEx stock lost another half percent Monday after JPMorgan lowered its price target on the stock to $184 from $202. Tennessee-based FedEx has been a guidance offender multiple times over the past year and it appears that bad news is poised to continue.Again, FedEx is not a Dow stock, nor is it the largest company in the U.S. Not even close, but transportation names are historically accurate gauges of economic sentiment the market's tolerance for risk so there could be some tests coming for stocks before June ends.As of this writing, Todd Shriber did not own any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 7 Best Tech Stocks to Buy for the Second Half of 2019 * 7 Top-Rated Biotech Stocks to Invest In Today * 4 Semiconductor Stocks to Sell Compare Brokers The post Dow Jones Today: Almost a Case of the Mondays appeared first on InvestorPlace.
The Dow Jones Industrial Average ended moderately higher Monday as investors moved cautiously heading into this week's Federal Reserve meeting and weighed renewed tariff threats from the White House. Facebook is Real Money's Stock of the Day. Stocks ended slightly higher on Monday as investors adopted a cautious stance going into this week's Federal Reserve meeting and amid renewed tariff threats from the White House.
Array BioPharma Inc. (Nasdaq: ARRY) has been acquired by Pfizer Inc. (NYSE: PFE). The Boulder-based biopharmaceutical firm focused on the commercialization of small molecule medicines to treat cancer and other diseases is being acquired for about $11.4 billion, or $48 per share. Upon approval by each company's board and the close of the deal, Array’s employees will join Pfizer and will continue to be located in Boulder.
Wall Street edged higher on Monday, supported by Facebook, Amazon and Apple, as investors awaited a key Federal Reserve meeting that is expected to lay the groundwork for an interest rate cut later this year. The U.S. central bank is expected to leave borrowing costs unchanged at its two-day policy meeting starting Tuesday, but its statement will provide insight into the impact of the U.S.-China trade war, President Donald Trump's calls for a rate cut and weaker economic data. With investors expecting a rate cut as early as July, the S&P 500 index has risen 5% this month after tumbling in May due to fears about the U.S.-China trade war.
Indices tiptoed higher on Monday, but investors are waiting to hear what the Federal Reserve has to say later this week before making any drastic moves. That's not stopping some companies from pouncing though, as M&A continues to be a theme over the last few weeks. Let's let a deal kick off our top stock trades for Tuesday. Top Stock Trades for Tomorrow 1: Pfizer Click to EnlargePfizer (NYSE:PFE) stock is in the news following its $11.4 billion acquisition of Array Biopharma (NASDAQ:ARRY) for $48 per share. The deal sent the latter up by more than 50%, while the former is trying to breakout over resistance as well.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Top-Rated Biotech Stocks to Invest In Today PFE stock has been a better sell than buy up near $43 to $43.50, and a solid buy down near $40. That said, with shares holding up on news of this deal -- actually eking out a gain on Monday -- and trading north of all three of its major moving averages, it looks okay on the long side.If it can clear $43.50 though, it WILL be setting up as a breakout. Over that and $45 is in sight, with even higher prices possible should PFE push through. Top Stock Trades for Tomorrow 2: Gilead Sciences Click to EnlargeThe PFE deal has biotech trading higher on the day and Gilead Sciences (NASDAQ:GILD) is no exception. Shares are up more than 1% on the day, as GILD stock pushes through its 200-day moving average.The 200-day happens to overlap with $76 range resistance, so perhaps this area knocks the stock down once more. However, if GILD can push through, a run up to $70 is possible. If it is resistance, a decline down to the 50-day is expected, with a possible decline down to uptrend support being possible. Top Stock Trades for Tomorrow 3: Tesla Click to EnlargeShares of Tesla (NASDAQ:TSLA) are moving really well on Monday, up over 5% on the day and up over $225. It puts the 50-day moving average in play currently at $231.45, as well as channel resistance near $235 to $240.Should Tesla rally this far, it would be a logical place to book profits for traders. Above it and former range support between $250 to $260 comes into play. In May that area acted as resistance for TSLA.On a pullback -- either from current levels or after tagging resistance -- see that channel support (blue line) holds. Ideally though, the 20-day will act as support for Tesla. Top Stock Trades for Tomorrow 4: Facebook Click to EnlargeThe big blue box on the Facebook (NASDAQ:FB) chart above represents the gap that was created from the company's disappointing quarterly results 11 months ago.Shares have pushed into this gap twice, in August 2018 and Q2 2019. Neither time has the stock been able to "fill" the gap all the way back up.With FB stock now jumping higher though, is the third time a charm? Maybe. Shares have climbed aggressive off the $160 lows and 200-day moving average, up almost $30 per share in just a few weeks. FB previously topped out near $196 and needs to push through this mark, as well as prior uptrend support (blue line) to fill the gap even more.The 61.8% is at $182.34, while the 50-day is at $182.18. So long as it holds $182, FB looks okay on the long side. Below and it can get a little choppier. Top Stock Trades for Tomorrow 5: Netflix Click to EnlargeNetflix (NASDAQ:NFLX) stock has been highly responsive to this $340 to $342 level. Buyers gobble it up each time NFLX dips in this area of range support. * The 7 Best Tech Stocks to Buy for the Second Half of 2019 That makes it a simple setup, and simple is what we like when it comes to trading. Below the 200-day and traders can cut their losses when dip-buying into this area. Now up a quick 10 points, let's see how NFLX handles the 50-day moving average. Above it could send Netflix to range resistance up near $380.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 7 Best Tech Stocks to Buy for the Second Half of 2019 * 7 Top-Rated Biotech Stocks to Invest In Today * 4 Semiconductor Stocks to Sell Compare Brokers The post 5 Top Stock Trades for Tuesday: FB, NFLX, GILD, TSLA appeared first on InvestorPlace.
The pharmaceutical company Pfizer said it would buy Array BioPharma, a maker of cancer drugs, for $48 a share in cash.
S&P Ratings has put Pfizer on watch for a downgrade after the pharma giant said it plans to acquire a cancer-drug maker.
The Dow Jones Industrial Average has gained nearly 12% so far in 2019. It doesn't seem like a whole heck of a lot, but considering the topsy-turvey markets of 2019, it's a pretty strong lift. That gain was driven by the majority of the Dow 30 as most of the stocks in the DJIA index contributed to its postive year-to-date gain.Microsoft (NASDAQ:MSFT) is the biggest winner of the bunch, gaining more than 30%. But owing to the odd price-weighted nature of the index, it's likely Visa (NYSE:V), with a 28% gain and a higher share price, that has been the biggest driver behind the Dow's gains.Not every component of the Dow Jones today has had a strong year, though. Five of the index's 30 stocks have declined so far this year. But not all of them make the list of the five worst Dow Jones stocks in 2019, which we'll recount in greater detail going forward.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Top-Rated Biotech Stocks to Invest In Today For reasons that go beyond pure performance, these five components have had the roughest year so far, which means they have the most to prove in the second half of 2019. Walgreens (WBA)Source: Mike Mozart via FlickrWalgreens (NASDAQ:WBA) is the easiest pick on the list. That's somewhat ironic considering that Walgreens is one of the index's newest members, replacing General Electric (NYSE:GE) just last year. WBA stock far and away has had the worst performance in 2019: its 22.6% decline is almost exactly twice as steep as that of the index's second-biggest decliner. WBA touched a five-year low late last month before a modest rally in recent weeks.As I wrote in April, disappointing store-level execution clearly has been a factor. But what might be more worrisome for WBA is that the entire retail pharmacy industry seems to under threat. Shares of rival CVS Health (NYSE:CVS), too, have touched a multi-year low.Smaller Rite Aid (NYSE:RAD) continues to plunge, with a hefty debt load adding to the pressure. Front-end sales aren't growing, and in pharmacy higher generic prices are compressing already-thin margins.WBA stock is cheap, now at less than 9x forward earnings. But right now, Walgreens looks a lot like most other retailers - and that will have to change for Walgreens stock to reverse its performance in not only 2019, but the last few years. Dow Inc. (DOW)Source: Roy Luck via Flickr (modified)It's a little unfair to put Dow Inc. (NYSE:DOW) on this list. DOW shares actually have gained 6% since they were spun off from what is now (again) DuPont (NYSE:DD) on April 1st.But DOW is part of the DowDuPont spinoff, a hugely complicated financial engineering project that was supposed to create real value for shareholders. It hasn't happened. DWDP shareholders received one share of Corteva (NYSE:CTVA) and one share of DOW for every three DowDuPont shares they owned. At current prices, that totals about $50 in value. DWDP shares closed 2018 near $54 - after declining 25% last year.This was a case where many value investors saw significant upside. Yet trade war concerns and post-spin trading have led DWDP to destroy value, at least so far. DOW and its former siblings still have time, and room, to rally. But a lot of smart investors likely see the YTD performance as among the most disappointing in their portfolios. Intel (INTC)Source: Shutterstock Performance-wise, Intel (NASDAQ:INTC) hasn't been a bad stock in 2019. It's underperformed the market, but a 0.5% decline actually turns very slightly positive when accounting for dividend payments.Still, 2019 hasn't been a good year for Intel. It's suffering chip shortages. It's still behind in 10nm -- and about four years late. Rival Advanced Micro Devices (NASDAQ:AMD) is gobbling up market share in CPUs. Apple (NASDAQ:AAPL) settled with Qualcomm (NASDAQ:QCOM) in large part because Intel couldn't move quick enough to get the iPhone to 5G.Intel still is a behemoth in the chip space, and the company still has time to right its ship. With INTC stock at barely 10x earnings, there's upside if and when that happens. But the company's performance so far this year inspires little confidence, which has been much weaker than a flattish stock price would imply. 3M (MMM)Source: Shutterstock The 11.4% decline in 3M (NYSE:MMM) shares so far this year is the second-worst performance in the Dow. But no component has posted a worse quarterly report than 3M did with its Q1 release in late April. 3M stock plunged 13%, its worst one-day decline in over 30 years. The drop was big enough to on its own pull the index down over 100 points.MMM stock still hasn't recovered: it would drop nearly another 20% in the following weeks before bottoming of late. And there's a case for the stock after the big decline, as James Brumley argued earlier this month. A 3.4% dividend yield helps the argument, and 3M's diversified business should allow it to ride out any further near-term or market volatility.Still, Q1 was an obvious concern: stocks like 3M don't fall 25% in a matter of weeks for no reason. And it was the automotive and Chinese markets that led to the poor quarter. Neither seems likely to rebound sharply all that soon. At the very least, it's going to take a lot more than one good quarter for 3M to make back what it lost after Q1. Pfizer (PFE)Source: Shutterstock It's a bit unfair to put Pfizer (NYSE:PFE) on this list. Pfizer certainly hasn't had a terrible year. PFE stock is down 2.6%, the third-worst performance in the index. But drugmakers generally underperform in bull markets, and many drug stocks have done worse in 2019. A 3.4% dividend yield offsets most of those losses anyhow.That said, Pfizer hasn't had a great year, either. Rival (and fellow Dow component) Merck (NYSE:MRK) has gained 8%-plus. And it's hard not to get the sense that PFE, which traded mostly sideways for over three years in the middle of the decade, is back to being stagnant. There doesn't seem to much of a catalyst on the horizon to change the Pfizer story, while external pressures on the industry continue to mount.It's true that, even this year, PFE shareholders could have done worse. But given that 25 Dow Jones stocks are up YTD, it's obvious they could have done better.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 7 Best Tech Stocks to Buy for the Second Half of 2019 * 7 Top-Rated Biotech Stocks to Invest In Today * 4 Semiconductor Stocks to Sell Compare Brokers The post The 5 Worst Dow Jones Stocks So Far in 2019 appeared first on InvestorPlace.
Pfizer stock has fallen 2% this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat. But the question remains: Is Pfizer stock a buy right now?
Today, Pfizer (PFE) announced its acquisition of Array BioPharma (ARRY). Pfizer will acquire Array BioPharma for $48 per share, which is a premium of roughly 62% over the stock’s June 14 closing price. The deal values Array Pharmaceuticals at an enterprise value of ~$11.4 billion.